Judith Regensteiner
Concepts (530)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intermittent Claudication | 46 | 2022 | 118 | 5.110 |
Why?
| | Diabetes Mellitus, Type 2 | 54 | 2024 | 2518 | 4.510 |
Why?
| | Sex Characteristics | 18 | 2024 | 759 | 3.440 |
Why?
| | Peripheral Arterial Disease | 24 | 2022 | 473 | 3.330 |
Why?
| | Exercise | 47 | 2024 | 2043 | 3.260 |
Why?
| | Exercise Therapy | 31 | 2022 | 436 | 2.950 |
Why?
| | Peripheral Vascular Diseases | 25 | 2011 | 103 | 2.560 |
Why?
| | Sex Factors | 20 | 2024 | 2060 | 2.290 |
Why?
| | Oxygen Consumption | 33 | 2021 | 695 | 2.120 |
Why?
| | Cardiovascular Diseases | 23 | 2024 | 2104 | 1.980 |
Why?
| | Walking | 23 | 2022 | 523 | 1.940 |
Why?
| | Diabetes Mellitus | 18 | 2024 | 1032 | 1.900 |
Why?
| | Women's Health | 10 | 2024 | 369 | 1.780 |
Why?
| | Biomedical Research | 8 | 2024 | 688 | 1.470 |
Why?
| | Exercise Test | 38 | 2019 | 625 | 1.420 |
Why?
| | Cardiology | 6 | 2023 | 274 | 1.210 |
Why?
| | Exercise Tolerance | 15 | 2024 | 279 | 1.170 |
Why?
| | American Heart Association | 10 | 2019 | 306 | 1.140 |
Why?
| | Quality of Life | 18 | 2019 | 2878 | 1.090 |
Why?
| | Leg | 13 | 2021 | 236 | 1.050 |
Why?
| | Research Personnel | 5 | 2024 | 171 | 1.040 |
Why?
| | Humans | 184 | 2024 | 136764 | 0.930 |
Why?
| | Mentoring | 3 | 2022 | 144 | 0.880 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2024 | 77 | 0.880 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.840 |
Why?
| | Diabetic Angiopathies | 6 | 2017 | 259 | 0.840 |
Why?
| | Vascular Stiffness | 3 | 2023 | 493 | 0.820 |
Why?
| | Female | 106 | 2024 | 72787 | 0.800 |
Why?
| | Muscle, Skeletal | 14 | 2024 | 1710 | 0.800 |
Why?
| | Male | 101 | 2024 | 67309 | 0.780 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 443 | 0.770 |
Why?
| | Community Health Services | 2 | 2015 | 227 | 0.770 |
Why?
| | Cardiovascular System | 5 | 2023 | 137 | 0.770 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2016 | 36 | 0.760 |
Why?
| | Education, Medical | 3 | 2020 | 260 | 0.750 |
Why?
| | Periodicals as Topic | 1 | 2024 | 208 | 0.740 |
Why?
| | Insulin Resistance | 12 | 2024 | 1203 | 0.700 |
Why?
| | Lower Extremity | 9 | 2019 | 423 | 0.680 |
Why?
| | Arterial Occlusive Diseases | 7 | 2015 | 80 | 0.670 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 27 | 0.660 |
Why?
| | Aged | 57 | 2024 | 23794 | 0.630 |
Why?
| | Cardiorespiratory Fitness | 2 | 2019 | 55 | 0.630 |
Why?
| | Middle Aged | 73 | 2024 | 33228 | 0.630 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 926 | 0.620 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 33 | 0.620 |
Why?
| | Obesity | 19 | 2023 | 2982 | 0.620 |
Why?
| | Diastole | 1 | 2019 | 149 | 0.600 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.600 |
Why?
| | Surveys and Questionnaires | 23 | 2018 | 5742 | 0.580 |
Why?
| | United States | 37 | 2024 | 14691 | 0.570 |
Why?
| | Physical Fitness | 9 | 2016 | 208 | 0.570 |
Why?
| | Gender Identity | 1 | 2019 | 124 | 0.570 |
Why?
| | Hypoglycemic Agents | 9 | 2021 | 1283 | 0.560 |
Why?
| | Metabolomics | 2 | 2020 | 678 | 0.550 |
Why?
| | Brachial Artery | 6 | 2015 | 201 | 0.540 |
Why?
| | Health Status | 4 | 2020 | 788 | 0.540 |
Why?
| | Mitochondria, Muscle | 4 | 2024 | 116 | 0.530 |
Why?
| | Hypertension | 6 | 2022 | 1284 | 0.530 |
Why?
| | Physical Exertion | 7 | 2009 | 215 | 0.530 |
Why?
| | Venoms | 1 | 2016 | 29 | 0.520 |
Why?
| | Blood Pressure | 12 | 2021 | 1774 | 0.520 |
Why?
| | Curriculum | 2 | 2020 | 976 | 0.510 |
Why?
| | Vasodilator Agents | 4 | 2010 | 331 | 0.510 |
Why?
| | Biomarkers | 6 | 2024 | 4143 | 0.480 |
Why?
| | Cardiac Rehabilitation | 3 | 2019 | 37 | 0.450 |
Why?
| | Research Design | 5 | 2024 | 1127 | 0.450 |
Why?
| | Life Style | 9 | 2018 | 487 | 0.440 |
Why?
| | National Institutes of Health (U.S.) | 4 | 2023 | 128 | 0.440 |
Why?
| | Arteriosclerosis | 5 | 2002 | 88 | 0.430 |
Why?
| | Sleep | 1 | 2020 | 753 | 0.420 |
Why?
| | Physicians | 5 | 2024 | 907 | 0.410 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2016 | 382 | 0.410 |
Why?
| | Faculty, Medical | 6 | 2024 | 283 | 0.410 |
Why?
| | Microcirculation | 4 | 2017 | 146 | 0.400 |
Why?
| | Home Care Services | 4 | 2019 | 257 | 0.400 |
Why?
| | Diabetes Mellitus, Type 1 | 9 | 2024 | 3710 | 0.400 |
Why?
| | Risk Factors | 29 | 2022 | 10326 | 0.390 |
Why?
| | Advisory Committees | 5 | 2019 | 219 | 0.380 |
Why?
| | Mentors | 4 | 2022 | 200 | 0.380 |
Why?
| | Blood Flow Velocity | 4 | 2009 | 412 | 0.370 |
Why?
| | Longevity | 3 | 2024 | 164 | 0.370 |
Why?
| | Adult | 40 | 2024 | 37630 | 0.340 |
Why?
| | Peptides | 1 | 2016 | 979 | 0.340 |
Why?
| | Disability Evaluation | 2 | 2011 | 290 | 0.340 |
Why?
| | Ankle | 3 | 2008 | 60 | 0.340 |
Why?
| | Weight Loss | 6 | 2016 | 776 | 0.330 |
Why?
| | Treatment Outcome | 24 | 2022 | 10744 | 0.330 |
Why?
| | Gait | 2 | 2006 | 296 | 0.320 |
Why?
| | Regional Blood Flow | 11 | 2020 | 473 | 0.310 |
Why?
| | Tetrazoles | 3 | 2006 | 40 | 0.310 |
Why?
| | Cardiac Output, Low | 1 | 2009 | 66 | 0.300 |
Why?
| | Physical Endurance | 3 | 2011 | 275 | 0.300 |
Why?
| | Thiazolidinediones | 3 | 2010 | 137 | 0.300 |
Why?
| | Double-Blind Method | 8 | 2019 | 1981 | 0.290 |
Why?
| | Oxygen | 4 | 2018 | 930 | 0.290 |
Why?
| | Research Support as Topic | 2 | 2020 | 119 | 0.290 |
Why?
| | Recovery of Function | 9 | 2019 | 652 | 0.290 |
Why?
| | Cost of Illness | 3 | 2018 | 302 | 0.290 |
Why?
| | Fear | 1 | 2011 | 338 | 0.280 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 193 | 0.280 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5106 | 0.270 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2020 | 133 | 0.270 |
Why?
| | Hematologic Agents | 1 | 2006 | 2 | 0.270 |
Why?
| | Blood Glucose | 10 | 2024 | 2181 | 0.260 |
Why?
| | Perception | 1 | 2009 | 359 | 0.260 |
Why?
| | Activities of Daily Living | 5 | 2021 | 413 | 0.260 |
Why?
| | Medicare | 2 | 2022 | 758 | 0.260 |
Why?
| | Caregivers | 3 | 2024 | 870 | 0.260 |
Why?
| | Stents | 6 | 2015 | 527 | 0.250 |
Why?
| | Disease Management | 4 | 2017 | 624 | 0.240 |
Why?
| | Motor Activity | 5 | 2012 | 717 | 0.240 |
Why?
| | Vascular Diseases | 4 | 2000 | 243 | 0.240 |
Why?
| | Foundations | 2 | 2018 | 28 | 0.240 |
Why?
| | Vascular Surgical Procedures | 5 | 2009 | 299 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2022 | 951 | 0.230 |
Why?
| | Pharmacovigilance | 1 | 2024 | 23 | 0.230 |
Why?
| | Interdisciplinary Studies | 2 | 2017 | 27 | 0.230 |
Why?
| | Societies, Medical | 3 | 2017 | 816 | 0.230 |
Why?
| | Echocardiography | 4 | 2018 | 642 | 0.230 |
Why?
| | Troponin | 1 | 2024 | 50 | 0.220 |
Why?
| | Troponin T | 1 | 2024 | 65 | 0.220 |
Why?
| | Vasodilation | 3 | 2015 | 496 | 0.220 |
Why?
| | Respiration | 3 | 1990 | 199 | 0.220 |
Why?
| | Fibrinolysis | 2 | 2003 | 143 | 0.220 |
Why?
| | Heart Rate | 6 | 2015 | 820 | 0.210 |
Why?
| | Insulin | 5 | 2020 | 2406 | 0.210 |
Why?
| | Troponin I | 1 | 2024 | 81 | 0.210 |
Why?
| | Overweight | 6 | 2023 | 557 | 0.210 |
Why?
| | Chest Pain | 1 | 2024 | 90 | 0.210 |
Why?
| | Medroxyprogesterone | 4 | 1991 | 11 | 0.210 |
Why?
| | Kinetics | 5 | 2015 | 1663 | 0.210 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 269 | 0.210 |
Why?
| | Lung Diseases | 3 | 2019 | 767 | 0.200 |
Why?
| | Muscles | 7 | 1994 | 325 | 0.200 |
Why?
| | Iliac Artery | 2 | 2014 | 55 | 0.200 |
Why?
| | Minority Groups | 2 | 2022 | 266 | 0.200 |
Why?
| | Polyhydroxyethyl Methacrylate | 1 | 2002 | 10 | 0.200 |
Why?
| | Financing, Organized | 2 | 2020 | 35 | 0.200 |
Why?
| | Financial Management | 1 | 2022 | 18 | 0.200 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 89 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 146 | 0.190 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 2022 | 0.190 |
Why?
| | Vitamin E | 1 | 2003 | 124 | 0.190 |
Why?
| | Orthopedics | 1 | 2024 | 142 | 0.190 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1571 | 0.190 |
Why?
| | Endovascular Procedures | 2 | 2018 | 311 | 0.190 |
Why?
| | Estrogens, Conjugated (USP) | 3 | 1991 | 49 | 0.180 |
Why?
| | Academic Medical Centers | 3 | 2020 | 504 | 0.180 |
Why?
| | Congresses as Topic | 2 | 2020 | 232 | 0.180 |
Why?
| | Ascorbic Acid | 1 | 2003 | 176 | 0.180 |
Why?
| | Organizational Innovation | 2 | 2020 | 138 | 0.180 |
Why?
| | Placebos | 3 | 2019 | 199 | 0.180 |
Why?
| | Arginine | 1 | 2003 | 271 | 0.180 |
Why?
| | Adiponectin | 2 | 2016 | 244 | 0.180 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 191 | 0.180 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2822 | 0.170 |
Why?
| | Qualitative Research | 3 | 2024 | 1366 | 0.170 |
Why?
| | Echocardiography, Doppler | 3 | 2016 | 108 | 0.170 |
Why?
| | Sulfonylurea Compounds | 2 | 2019 | 48 | 0.170 |
Why?
| | Sex Distribution | 2 | 2020 | 373 | 0.170 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 178 | 0.170 |
Why?
| | Precision Medicine | 2 | 2024 | 426 | 0.170 |
Why?
| | Cardiovascular Agents | 2 | 2014 | 159 | 0.160 |
Why?
| | Patient Compliance | 4 | 2015 | 577 | 0.160 |
Why?
| | Time Factors | 11 | 2018 | 6806 | 0.160 |
Why?
| | Hemodynamics | 6 | 2009 | 1110 | 0.160 |
Why?
| | Forearm | 2 | 2015 | 118 | 0.160 |
Why?
| | Arteries | 3 | 2016 | 269 | 0.160 |
Why?
| | Clinical Trials as Topic | 6 | 2019 | 1044 | 0.160 |
Why?
| | Case-Control Studies | 7 | 2024 | 3540 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2006 | 1462 | 0.150 |
Why?
| | Pediatric Obesity | 2 | 2017 | 590 | 0.150 |
Why?
| | Body Composition | 5 | 2014 | 679 | 0.150 |
Why?
| | Telerehabilitation | 1 | 2019 | 37 | 0.150 |
Why?
| | Body Mass Index | 9 | 2017 | 2375 | 0.150 |
Why?
| | Adolescent | 12 | 2022 | 21382 | 0.150 |
Why?
| | Cross-Sectional Studies | 8 | 2014 | 5423 | 0.150 |
Why?
| | Cause of Death | 1 | 2020 | 430 | 0.140 |
Why?
| | Women's Rights | 1 | 2017 | 4 | 0.140 |
Why?
| | Diabetes Complications | 4 | 2010 | 226 | 0.140 |
Why?
| | Leadership | 2 | 2020 | 382 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2024 | 440 | 0.140 |
Why?
| | Pentoxifylline | 3 | 2006 | 25 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2024 | 610 | 0.140 |
Why?
| | Health Status Indicators | 4 | 2015 | 168 | 0.140 |
Why?
| | Aged, 80 and over | 9 | 2012 | 7585 | 0.140 |
Why?
| | Sexism | 1 | 2018 | 61 | 0.140 |
Why?
| | Interviews as Topic | 4 | 2024 | 772 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 364 | 0.140 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 185 | 0.140 |
Why?
| | Resistance Training | 1 | 2020 | 163 | 0.140 |
Why?
| | Heart Diseases | 2 | 2019 | 346 | 0.130 |
Why?
| | Circadian Rhythm | 2 | 2020 | 468 | 0.130 |
Why?
| | Colorado | 9 | 2017 | 4518 | 0.130 |
Why?
| | Ankle Brachial Index | 2 | 2014 | 37 | 0.130 |
Why?
| | Capillaries | 3 | 2012 | 108 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 85 | 0.130 |
Why?
| | Glucose Tolerance Test | 4 | 2024 | 364 | 0.120 |
Why?
| | Faculty | 1 | 2017 | 146 | 0.120 |
Why?
| | Ischemia | 1 | 2019 | 407 | 0.120 |
Why?
| | Reference Values | 4 | 2007 | 816 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 187 | 0.120 |
Why?
| | Needs Assessment | 1 | 2018 | 372 | 0.120 |
Why?
| | Leptin | 1 | 2017 | 236 | 0.120 |
Why?
| | Plethysmography | 3 | 2011 | 106 | 0.120 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 73 | 0.120 |
Why?
| | Adiposity | 2 | 2017 | 518 | 0.120 |
Why?
| | Program Evaluation | 2 | 2020 | 889 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2018 | 283 | 0.110 |
Why?
| | Myocardium | 1 | 2020 | 1001 | 0.110 |
Why?
| | Ventricular Function | 1 | 2015 | 61 | 0.110 |
Why?
| | Cardiac Output | 1 | 2015 | 164 | 0.110 |
Why?
| | Physical Education and Training | 1 | 1994 | 76 | 0.110 |
Why?
| | Pilot Projects | 2 | 2015 | 1692 | 0.110 |
Why?
| | Endothelium | 1 | 2015 | 122 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1314 | 0.110 |
Why?
| | Arterial Pressure | 1 | 2015 | 126 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.110 |
Why?
| | Patient Selection | 4 | 2019 | 690 | 0.110 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1995 | 128 | 0.110 |
Why?
| | Health Care Costs | 2 | 2014 | 384 | 0.110 |
Why?
| | Hyperlipidemias | 3 | 2004 | 120 | 0.110 |
Why?
| | Hypoxia | 3 | 1990 | 1112 | 0.100 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 23 | 0.100 |
Why?
| | Angioplasty | 2 | 2009 | 47 | 0.100 |
Why?
| | Aortic Diseases | 1 | 2014 | 117 | 0.100 |
Why?
| | Menopause | 3 | 1991 | 319 | 0.100 |
Why?
| | Reaction Time | 1 | 2015 | 412 | 0.100 |
Why?
| | Diet, Reducing | 1 | 2013 | 89 | 0.100 |
Why?
| | Carnitine | 5 | 2001 | 84 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 533 | 0.100 |
Why?
| | Diabetic Nephropathies | 2 | 2014 | 294 | 0.090 |
Why?
| | Students, Medical | 1 | 2017 | 339 | 0.090 |
Why?
| | Capacity Building | 1 | 2012 | 63 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2024 | 15504 | 0.090 |
Why?
| | Premenopause | 2 | 2003 | 131 | 0.090 |
Why?
| | Counseling | 1 | 2015 | 388 | 0.090 |
Why?
| | Smoking | 6 | 2010 | 1620 | 0.090 |
Why?
| | Myocardial Revascularization | 1 | 2011 | 73 | 0.090 |
Why?
| | Clinical Protocols | 1 | 1993 | 267 | 0.090 |
Why?
| | Kidney | 2 | 2021 | 1467 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2016 | 785 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 734 | 0.090 |
Why?
| | Linear Models | 2 | 2014 | 846 | 0.090 |
Why?
| | Research Report | 1 | 2011 | 83 | 0.090 |
Why?
| | Benchmarking | 1 | 2012 | 183 | 0.090 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 56 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2009 | 159 | 0.090 |
Why?
| | Hemoglobins | 2 | 2017 | 353 | 0.090 |
Why?
| | Hyperemia | 1 | 2011 | 49 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 249 | 0.090 |
Why?
| | Comorbidity | 4 | 2021 | 1614 | 0.090 |
Why?
| | Coronary Disease | 4 | 2004 | 384 | 0.080 |
Why?
| | Consensus | 3 | 2019 | 678 | 0.080 |
Why?
| | Niacin | 1 | 2010 | 17 | 0.080 |
Why?
| | Affect | 1 | 2012 | 292 | 0.080 |
Why?
| | Lovastatin | 1 | 2010 | 37 | 0.080 |
Why?
| | Atherosclerosis | 2 | 2011 | 415 | 0.080 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2009 | 130 | 0.080 |
Why?
| | Young Adult | 6 | 2024 | 13129 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2009 | 408 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2002 | 462 | 0.080 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.080 |
Why?
| | Gonadal Steroid Hormones | 1 | 1990 | 140 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2009 | 59 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 543 | 0.080 |
Why?
| | Hyperinsulinism | 2 | 2010 | 121 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 69 | 0.080 |
Why?
| | Aorta | 1 | 2011 | 417 | 0.080 |
Why?
| | Thinness | 1 | 2009 | 91 | 0.080 |
Why?
| | Hospitalization | 1 | 2018 | 2183 | 0.070 |
Why?
| | Psychometrics | 1 | 2012 | 719 | 0.070 |
Why?
| | Heart Failure | 3 | 2018 | 2231 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2012 | 1316 | 0.070 |
Why?
| | Fasting | 2 | 2005 | 280 | 0.070 |
Why?
| | Age Factors | 4 | 2021 | 3284 | 0.070 |
Why?
| | Puberty | 1 | 2009 | 146 | 0.070 |
Why?
| | Perfusion | 1 | 2009 | 211 | 0.070 |
Why?
| | Angina Pectoris | 1 | 2008 | 65 | 0.070 |
Why?
| | Cost-Benefit Analysis | 4 | 2014 | 587 | 0.070 |
Why?
| | Myoglobin | 1 | 2007 | 13 | 0.070 |
Why?
| | Leisure Activities | 2 | 2006 | 32 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 946 | 0.070 |
Why?
| | Inflammation | 3 | 2009 | 2834 | 0.070 |
Why?
| | Aging | 1 | 2018 | 1861 | 0.070 |
Why?
| | Awareness | 1 | 2008 | 102 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1320 | 0.060 |
Why?
| | Prospective Studies | 8 | 2019 | 7572 | 0.060 |
Why?
| | Prevalence | 3 | 2019 | 2711 | 0.060 |
Why?
| | Regression Analysis | 5 | 1998 | 1022 | 0.060 |
Why?
| | Dyspnea | 1 | 2008 | 254 | 0.060 |
Why?
| | Glycation End Products, Advanced | 1 | 2006 | 82 | 0.060 |
Why?
| | Chronic Disease | 2 | 2023 | 1784 | 0.060 |
Why?
| | Blood Viscosity | 2 | 1995 | 17 | 0.060 |
Why?
| | Metformin | 2 | 2010 | 330 | 0.060 |
Why?
| | Pulmonary Circulation | 1 | 2007 | 429 | 0.060 |
Why?
| | Neoplasms | 2 | 2010 | 2644 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 195 | 0.060 |
Why?
| | Hematocrit | 2 | 1995 | 96 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2004 | 308 | 0.060 |
Why?
| | Sulfonic Acids | 1 | 2004 | 13 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2009 | 778 | 0.060 |
Why?
| | Guilt | 1 | 2024 | 11 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 665 | 0.060 |
Why?
| | Animals | 5 | 2018 | 36823 | 0.060 |
Why?
| | Nutrition Surveys | 1 | 2006 | 266 | 0.060 |
Why?
| | Population Dynamics | 1 | 1985 | 149 | 0.060 |
Why?
| | Work-Life Balance | 1 | 2024 | 21 | 0.060 |
Why?
| | Acetates | 1 | 2004 | 99 | 0.050 |
Why?
| | Estrogens | 2 | 2010 | 367 | 0.050 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 97 | 0.050 |
Why?
| | Cohort Studies | 3 | 2016 | 5701 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2792 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 155 | 0.050 |
Why?
| | Biopsy | 3 | 2012 | 1124 | 0.050 |
Why?
| | Body Weight | 2 | 2006 | 985 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 91 | 0.050 |
Why?
| | Physicians, Women | 1 | 2024 | 82 | 0.050 |
Why?
| | Intracranial Arterial Diseases | 1 | 2002 | 8 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2004 | 317 | 0.050 |
Why?
| | Dietary Fats | 1 | 2004 | 304 | 0.050 |
Why?
| | Child | 5 | 2017 | 21822 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 301 | 0.050 |
Why?
| | Serum Globulins | 1 | 2002 | 5 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 319 | 0.050 |
Why?
| | Musculoskeletal Diseases | 1 | 2003 | 77 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2004 | 293 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 4013 | 0.050 |
Why?
| | Lung | 1 | 2015 | 4052 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2002 | 86 | 0.050 |
Why?
| | Pelvis | 1 | 2002 | 102 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2004 | 309 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2013 | 282 | 0.050 |
Why?
| | Ambulatory Care | 2 | 2014 | 539 | 0.050 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2001 | 87 | 0.050 |
Why?
| | Proteinuria | 1 | 2001 | 97 | 0.040 |
Why?
| | Alcohol Drinking | 2 | 2010 | 820 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2005 | 630 | 0.040 |
Why?
| | Homocysteine | 1 | 2002 | 156 | 0.040 |
Why?
| | Diet | 2 | 2010 | 1274 | 0.040 |
Why?
| | Physical Examination | 1 | 2002 | 240 | 0.040 |
Why?
| | Patient Satisfaction | 2 | 2002 | 656 | 0.040 |
Why?
| | Fibrinogen | 1 | 2002 | 167 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 839 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 267 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2002 | 186 | 0.040 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2000 | 30 | 0.040 |
Why?
| | Multivariate Analysis | 3 | 2014 | 1507 | 0.040 |
Why?
| | Altitude | 1 | 1985 | 485 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 201 | 0.040 |
Why?
| | Administration, Oral | 1 | 2003 | 813 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2002 | 223 | 0.040 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 365 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 262 | 0.040 |
Why?
| | Internal Medicine | 1 | 2002 | 260 | 0.040 |
Why?
| | Medroxyprogesterone Acetate | 2 | 1990 | 36 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 769 | 0.040 |
Why?
| | Specialties, Surgical | 1 | 2000 | 74 | 0.040 |
Why?
| | Organization and Administration | 1 | 2019 | 12 | 0.040 |
Why?
| | Pregnancy | 3 | 2020 | 6728 | 0.040 |
Why?
| | Femoral Artery | 2 | 2011 | 179 | 0.040 |
Why?
| | Sports Medicine | 2 | 2010 | 112 | 0.040 |
Why?
| | Rural Population | 2 | 1995 | 560 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 78 | 0.040 |
Why?
| | Asia | 1 | 2018 | 70 | 0.040 |
Why?
| | Densitometry | 1 | 1998 | 36 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2551 | 0.040 |
Why?
| | Lactic Acid | 2 | 1998 | 305 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 131 | 0.040 |
Why?
| | Hypercapnia | 2 | 1989 | 53 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 134 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 244 | 0.040 |
Why?
| | Walking Speed | 1 | 2018 | 45 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 350 | 0.040 |
Why?
| | Cell Respiration | 1 | 2018 | 102 | 0.040 |
Why?
| | Autonomic Nervous System | 1 | 1998 | 75 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 232 | 0.040 |
Why?
| | Public Health | 1 | 2023 | 579 | 0.040 |
Why?
| | Walk Test | 1 | 2018 | 76 | 0.030 |
Why?
| | Hand Strength | 1 | 2018 | 122 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2002 | 436 | 0.030 |
Why?
| | Neural Conduction | 2 | 1995 | 86 | 0.030 |
Why?
| | Depression | 1 | 2007 | 1395 | 0.030 |
Why?
| | Capillary Resistance | 1 | 2017 | 5 | 0.030 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 64 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1062 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Career Choice | 1 | 2019 | 216 | 0.030 |
Why?
| | Acute Disease | 1 | 2020 | 1004 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 23 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 116 | 0.030 |
Why?
| | Family Practice | 1 | 2001 | 462 | 0.030 |
Why?
| | Caloric Restriction | 1 | 2018 | 123 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2013 | 3264 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 56 | 0.030 |
Why?
| | Canada | 1 | 2018 | 417 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 114 | 0.030 |
Why?
| | Heart | 1 | 2020 | 653 | 0.030 |
Why?
| | Forecasting | 2 | 2000 | 386 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1935 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 616 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 372 | 0.030 |
Why?
| | Stroke Volume | 1 | 2018 | 612 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 39 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2016 | 254 | 0.030 |
Why?
| | Energy Intake | 3 | 2006 | 484 | 0.030 |
Why?
| | Risk | 1 | 2017 | 908 | 0.030 |
Why?
| | Electrophysiology | 1 | 1995 | 217 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 65 | 0.030 |
Why?
| | Vascular Patency | 1 | 2014 | 103 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 113 | 0.030 |
Why?
| | Models, Economic | 1 | 2014 | 58 | 0.030 |
Why?
| | Life Expectancy | 1 | 2014 | 68 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 761 | 0.030 |
Why?
| | Phosphorus | 1 | 2014 | 97 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 481 | 0.030 |
Why?
| | Hospital Costs | 1 | 2014 | 116 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 242 | 0.030 |
Why?
| | Databases, Factual | 2 | 2011 | 1351 | 0.030 |
Why?
| | Drug Costs | 1 | 2014 | 106 | 0.030 |
Why?
| | Health Behavior | 1 | 2019 | 756 | 0.030 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 145 | 0.030 |
Why?
| | Health Education | 1 | 2016 | 338 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 204 | 0.030 |
Why?
| | Collateral Circulation | 2 | 2003 | 19 | 0.030 |
Why?
| | Carotid Stenosis | 1 | 2014 | 91 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 806 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 499 | 0.020 |
Why?
| | Administrative Personnel | 1 | 2012 | 29 | 0.020 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 127 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 307 | 0.020 |
Why?
| | Waist Circumference | 1 | 2012 | 143 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 738 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1132 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 354 | 0.020 |
Why?
| | Health Planning | 1 | 1992 | 47 | 0.020 |
Why?
| | North Carolina | 1 | 2012 | 107 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1613 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 71 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 317 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2014 | 423 | 0.020 |
Why?
| | Popliteal Artery | 1 | 2011 | 59 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1992 | 96 | 0.020 |
Why?
| | Estrone | 1 | 1991 | 37 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2014 | 258 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1991 | 173 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 888 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2014 | 745 | 0.020 |
Why?
| | Follicular Phase | 1 | 1990 | 39 | 0.020 |
Why?
| | C-Peptide | 1 | 1991 | 163 | 0.020 |
Why?
| | Metabolism | 1 | 1990 | 42 | 0.020 |
Why?
| | Luteal Phase | 1 | 1990 | 45 | 0.020 |
Why?
| | Incretins | 1 | 2010 | 22 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 65 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2010 | 105 | 0.020 |
Why?
| | Actigraphy | 1 | 2010 | 110 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 549 | 0.020 |
Why?
| | Acetylcarnitine | 1 | 1989 | 5 | 0.020 |
Why?
| | Health Services Research | 1 | 2012 | 399 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 478 | 0.020 |
Why?
| | Progesterone | 1 | 1991 | 254 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2010 | 180 | 0.020 |
Why?
| | Risk Assessment | 2 | 2009 | 3432 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1163 | 0.020 |
Why?
| | Respiration Disorders | 1 | 1989 | 77 | 0.020 |
Why?
| | Energy Metabolism | 3 | 2006 | 919 | 0.020 |
Why?
| | Partial Pressure | 1 | 1988 | 30 | 0.020 |
Why?
| | Estradiol | 1 | 1991 | 518 | 0.020 |
Why?
| | Tidal Volume | 1 | 1988 | 86 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 407 | 0.020 |
Why?
| | Pain | 1 | 1993 | 754 | 0.020 |
Why?
| | Ankle Joint | 1 | 2008 | 114 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 218 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 51 | 0.020 |
Why?
| | Caspase 3 | 1 | 2007 | 246 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2010 | 347 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2007 | 195 | 0.020 |
Why?
| | Testosterone | 1 | 2010 | 401 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2829 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 33 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2007 | 810 | 0.020 |
Why?
| | Income | 1 | 2007 | 202 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 1988 | 267 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 1989 | 283 | 0.010 |
Why?
| | Sterol O-Acyltransferase | 1 | 2004 | 5 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 2006 | 216 | 0.010 |
Why?
| | Acetamides | 1 | 2004 | 36 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 66 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 389 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2004 | 181 | 0.010 |
Why?
| | Gene Transfer Techniques | 1 | 2004 | 169 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2004 | 218 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 495 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 382 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3555 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2083 | 0.010 |
Why?
| | Endpoint Determination | 1 | 2001 | 77 | 0.010 |
Why?
| | Lactates | 2 | 1992 | 85 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2001 | 123 | 0.010 |
Why?
| | Sulfonamides | 1 | 2004 | 513 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1689 | 0.010 |
Why?
| | Attitude | 1 | 2002 | 259 | 0.010 |
Why?
| | Wound Healing | 1 | 2003 | 328 | 0.010 |
Why?
| | World Health Organization | 1 | 2000 | 123 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 206 | 0.010 |
Why?
| | Artificial Limbs | 1 | 2003 | 199 | 0.010 |
Why?
| | Logistic Models | 1 | 2004 | 2067 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1773 | 0.010 |
Why?
| | Indians, North American | 1 | 2004 | 629 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 2002 | 396 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2002 | 1282 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 1998 | 93 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2000 | 575 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1998 | 189 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 1996 | 216 | 0.010 |
Why?
| | Rehabilitation | 1 | 1992 | 19 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1991 | 203 | 0.010 |
Why?
| | Hydroxybutyrates | 1 | 1989 | 14 | 0.010 |
Why?
| | Electromyography | 1 | 1992 | 401 | 0.010 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 1989 | 17 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 1989 | 74 | 0.000 |
Why?
| | Nervous System Diseases | 1 | 1992 | 263 | 0.000 |
Why?
| | Ultrasonics | 1 | 1989 | 49 | 0.000 |
Why?
| | Action Potentials | 1 | 1992 | 493 | 0.000 |
Why?
| | Sleep Apnea Syndromes | 1 | 1989 | 88 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 343 | 0.000 |
Why?
| | Mice | 1 | 1989 | 17733 | 0.000 |
Why?
|
|
Regensteiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|